Results 81 to 90 of about 157,234 (246)

Monoaminergic Neuropathology in Alzheimer's disease [PDF]

, 2016
Acknowledgments This work was supported by The Croatian Science Foundation grant. no. IP-2014-09-9730 (“Tau protein hyperphosphorylation, aggregation, and trans-synaptic transfer in Alzheimer’s disease: cerebrospinal fluid analysis and assessment of ...
Bažadona, Danira, Buée, Luc, Delalle, Ivana, Giovanni, Giuseppe Di, Harrington, Charles R., Hof, Patrick R., Jovanov-Milošević, Nataša, Leko, Mirjana Babić, Silva, Rohan de, Wischik, Claude M., Wray, Selina, Šimić, Goran   +11 more
core   +1 more source

Additional file 1: of Attitudes toward clinical trials across the Alzheimerâ s disease spectrum

, 2017
Appendix. (DOC 59 kb)
NuĂąo, Michelle, Gillen, Daniel, Dosanjh, Kulwant, Brook, Jenny, Elashoff, David, Ringman, John, Grill, Joshua   +6 more
openaire   +1 more source

Will Memantine Exacerbate Seizures in People With Epilepsy? A Prospective Cohort Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate whether add‐on memantine would exacerbate seizures in people with epilepsy. Methods This was a prospective cohort study. People with epilepsy diagnosed with cognitive impairment were consecutively invited. Those who agreed were followed up for at least 24 weeks.
Peiyu Wang, Lu Lu, Hui Gao, Qi Zhang, Jing Xiao, Josemir W. Sander, Weixi Xiong, Dong Zhou   +7 more
wiley   +1 more source

Relationships of change in Clinical Dementia Rating (CDR) on patient outcomes and probability of progression: observational analysis

Alzheimer’s Research & Therapy
Background Understanding the relationship among changes in Clinical Dementia Rating (CDR), patient outcomes, and probability of progression is crucial for evaluating the long-term benefits of disease-modifying treatments.
Pierre N. Tariot, Mercè Boada, Krista L. Lanctôt, Julie Hahn-Pedersen, Firas Dabbous, Sariya Udayachalerm, Lars Lau Raket, Yuliya Halchenko, Wojciech Michalak, Wendy Weidner, Jeffrey Cummings   +10 more
doaj   +1 more source

Evaluation of gene-based family-based methods to detect novel genes associated with familial late onset Alzheimer disease [PDF]

, 2018
Gene-based tests to study the combined effect of rare variants towards a particular phenotype have been widely developed for case-control studies, but their evolution and adaptation for family-based studies, especially for complex incomplete families ...
Budde, John, Cruchaga, Carlos, Del-Aguila, Jorge L, Deming, Yuetiva, Fernandez, Maria V, Goate, Alison M, Harari, Oscar, Ibanez, Laura, Morris, John C, NCRAD,, NIA-LOAD family study group,, Norton, Joanne   +11 more
core   +2 more sources

KNOWING CHOLESTEROL EFFECTS ON ALZHEIMER’S DISEASE

Jurnal Kedokteran dan Kesehatan Indonesia, 2015
No ...
openaire   +4 more sources

Discovery and Targeted Proteomic Studies Reveal Striatal Markers Validated for Huntington's Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Clinical trials for Huntington's disease (HD) enrolling persons before clinical motor diagnosis (CMD) lack validated biomarkers. This study aimed to conduct an unbiased discovery analysis and a targeted examination of proteomic biomarkers scrutinized by clinical validation. Methods Cerebrospinal fluid was obtained from PREDICT‐HD and
Daniel Chelsky, Cara Joyce, H. Jeremy Bockholt, Paul A. Rudnick, William H. Adams, Fiona McAllister, Justin W. Smock, Michael A. Newton, Jane S. Paulsen   +8 more
wiley   +1 more source

Risk factors for Alzheimer’s disease

Folia Neuropathologica, 2019
Early reviews identified over 20 risk factors associated with Alzheimer’s disease (AD) including age, familial inheritance, exposure to aluminium, traumatic brain injury (TBI), and associated co-morbidities such as vascular disease and infection.
Richard A. Armstrong
doaj   +1 more source

An Out‐of‐Place Etiology: Recognizing FMR1 Premutation in the Memory Clinic

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT The FMR1 gene premutation (55–200 CGG repeats) is usually associated with a wide range of symptoms and phenotypes within the Fragile X‐tremor/ataxia syndrome (FXTAS), but may also manifest as predominant or isolated cognitive decline. We describe three male patients referred for progressive cognitive impairment and behavioral changes. Standard
Guido Greco, Caterina Motta, Enrica Marchionni, Maria Rosaria D'Apice, Carlangelo Carrese, Giuseppe Novelli, Alessandro Martorana, Chiara Giuseppina Bonomi   +7 more
wiley   +1 more source

Language impairment in Alzheimer's disease and benefits of acetylcholinesterase inhibitors

Clinical Interventions in Aging, 2013
Steven H Ferris,1 Martin Farlow21Alzheimer's Disease Center, Comprehensive Center on Brain Aging, New York University Langone Medical Center, New York, NY, 2Department of Neurology, Indiana University School of Medicine, Indianapolis, IN, USAAbstract:
Ferris SH, Farlow M
doaj